Borderline total testosterone results require accurate free testosterone testing methods to properly evaluate SHBG variations and confirm true bioavailable hormone levels.
This article is for educational and informational purposes only. It does not provide medical advice, diagnosis, or treatment protocols. Interpreting hormone test results requires a comprehensive medical evaluation by a qualified healthcare professional. Never start, stop, or change any medical treatment based on laboratory numbers alone.
You open your patient portal to review your latest blood test results. Your total testosterone level sits comfortably in the middle of the reference range. Yet right below it, your free testosterone is marked with a red alert showing an abnormally low value. A few months later, a different laboratory uses a different testing method and reports that your free testosterone is completely normal.
This confusing scenario happens frequently in male hormone testing. Free testosterone represents the unbound fraction of hormone circulating in your bloodstream. Because it makes up only a tiny percentage of the total hormone pool, measuring it accurately is difficult. Laboratories rely on three distinct testing strategies: equilibrium dialysis, mathematical calculations, and direct analog immunoassays.
These testing strategies do not measure the hormone in the same way. They yield different numbers, rely on different assumptions, and have very different levels of scientific accuracy. Understanding how these methods work will help you interpret your lab report with clarity.
Total testosterone measures all testosterone molecules circulating in your bloodstream. In healthy men, the vast majority of this hormone is bound tightly or loosely to proteins. Sex hormone-binding globulin, known as SHBG, binds roughly 40 to 60 percent of circulating testosterone with high affinity. Albumin binds another 30 to 50 percent of the hormone with much weaker affinity.
The remaining one to four percent remains entirely unbound. This unbound portion is called free testosterone. Because it is unattached to carrier proteins, free testosterone can diffuse across cell membranes and interact directly with androgen receptors in tissues throughout the body.
Total testosterone remains the primary initial screening test for male hypogonadism. However, measuring total testosterone alone can produce misleading conclusions when protein binding is altered. When SHBG levels shift significantly up or down, total testosterone concentrations change even if true free hormone availability remains steady.
Clinical guidelines from the Endocrine Society identify specific clinical situations where free testosterone testing provides essential diagnostic clarity.
When morning total testosterone falls into a borderline range, measuring free testosterone helps clarify the clinical picture. The Endocrine Society identifies 200 to 400 ng/dL as a representative borderline range where binding abnormalities may mask normal or deficient free hormone levels.
If total testosterone is severely suppressed, such as below 150 ng/dL, measuring free testosterone is generally unnecessary. In those cases, free testosterone is almost universally low. When results sit in the borderline zone, free testosterone testing helps clinicians distinguish true androgen deficiency from binding variations.
When SHBG is abnormally low, total testosterone drops because there are fewer binding sites available in circulation. In this scenario, free testosterone may remain completely normal despite a low total testosterone number. Men in this category can be incorrectly diagnosed with hypogonadism if doctors evaluate total testosterone in isolation.
Common clinical conditions and medications that lower SHBG concentrations include:
When SHBG is abnormally elevated, the protein binds a larger fraction of circulating testosterone. This can elevate total testosterone into the normal range even when the free, active fraction is low. Men with high SHBG may experience symptoms of androgen deficiency while their total testosterone numbers look completely reassuring.
Common factors and medical conditions that raise SHBG concentrations include:
Understanding these clinical factors prevents misinterpreting laboratory reports. You can read more about these mechanisms across our basics of testosterone physiology guides.
Interpreting a free testosterone test requires looking at several interrelated biomarkers simultaneously. A single biomarker in isolation never tells the full physiological story.
Total testosterone reflects the overall concentration of androgen molecules present in serum. It is measured in nanograms per deciliter (ng/dL) or nanomoles per liter (nmol/L). Reliable measurement requires liquid chromatography-tandem mass spectrometry or well-validated automated platforms. Because testosterone follows a strict circadian rhythm, blood samples must be drawn between 7:00 AM and 10:00 AM after an overnight fast.
Free testosterone quantifies the unbound hormone fraction. It is typically reported in picograms per milliliter (pg/mL), nanograms per deciliter (ng/dL), or picomoles per liter (pmol/L). Because concentrations are very low, assays must detect small amounts of hormone with high precision. Free testosterone testing provides the most accurate indicator of tissue androgen exposure when SHBG fluctuates.
SHBG is a glycoprotein produced by the liver that binds androgens and estrogens. It is measured in nanomoles per liter (nmol/L). SHBG regulates hormone bioavailability and clears sex steroids from systemic circulation. Monitoring SHBG alongside testosterone is essential for calculating free hormone levels and identifying metabolic liver changes.
Albumin is the most abundant protein in human plasma and is measured in grams per deciliter (g/dL). While SHBG binds testosterone tightly, albumin binds testosterone loosely. This low-affinity binding allows albumin-bound testosterone to dissociate rapidly in tissue capillary beds. In mathematical equations for free testosterone, measured albumin provides a key variable for calculating accurate binding states.
Bioavailable testosterone refers to the combined sum of free testosterone and albumin-bound testosterone. Because albumin-bound hormone dissociates easily, bioavailable testosterone represents the total fraction theoretically accessible to tissues. Bioavailable testosterone is a distinct measurement and must not be used interchangeably with free testosterone. You can explore our dedicated testosterone testing resources to see how these fractions compare.
Laboratories use three primary methods to determine free testosterone. Each method relies on distinct biochemical principles and carries specific strengths and vulnerabilities.
Equilibrium dialysis is widely regarded by professional societies as the reference standard for measuring free testosterone. This technique physically isolates the unbound hormone before measurement rather than estimating it through a mathematical formula.
The laboratory places a patient serum sample into one compartment of a specialized dialysis chamber. A semipermeable membrane separates this compartment from a second chamber containing an identical volume of protein-free buffer. The membrane features a strict molecular weight cutoff, usually between 5,000 and 10,000 Daltons.
Large proteins such as SHBG and albumin cannot pass through the microscopic pores of the membrane. Free testosterone molecules are small enough to pass back and forth across the barrier. The sample is incubated until the concentration of free testosterone reaches thermodynamic equilibrium on both sides of the membrane.
Once equilibrium is reached, the laboratory extracts the dialysate buffer, which contains only the unbound hormone. The concentration of testosterone in that dialysate is then quantified using sensitive mass spectrometry (LC-MS/MS).
Calculated free testosterone uses mathematical modeling based on the law of mass action. Instead of physically separating the hormone, a formula predicts free testosterone using total testosterone, SHBG, and albumin measurements.
The mathematical model assumes that testosterone, SHBG, and albumin interact in a predictable chemical equilibrium. The equations incorporate established association binding constants for testosterone binding to SHBG and albumin.
The most widely utilized formula in clinical medicine is the Vermeulen equation, developed in 1999. Other published models include the Sodergard formula and newer allosteric models that account for multi-step binding interactions on the SHBG dimer.
Direct analog immunoassays are commercial kits designed to measure free testosterone directly in a standard automated analyzer. They are sold under names like direct free testosterone radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA).
These assays use a chemically modified testosterone molecule called an analog that is linked to a signal tracer. The assay assumes the analog will compete with free testosterone for binding to an antibody without binding to SHBG or albumin. The measured signal is then used to calculate the free testosterone concentration.
To learn more about diagnostic standards, review our guides on testing and biomarker guides.
Patients are often confused when different laboratories report drastically different free testosterone numbers from blood drawn just weeks apart. These discrepancies stem from genuine differences in laboratory methodology, mathematical assumptions, and reference populations.
Equilibrium dialysis and calculated free testosterone approach the measurement from entirely different angles. Equilibrium dialysis isolates the physical hormone molecules present in an unbound state. Calculated free testosterone predicts how many molecules should be unbound based on theoretical physics.
If a patient possesses an atypical SHBG variant with an altered binding affinity, mathematical equations using standard binding constants will miscalculate the free hormone fraction. Equilibrium dialysis, by contrast, captures the actual physical distribution regardless of genetic binding variations.
Not all calculation formulas use the same mathematical assumptions. Published equations differ in the association constants they assign to the binding of testosterone to SHBG and albumin.
Scientific evaluations have shown that commonly used equations systematically overestimate free testosterone when compared directly to equilibrium dialysis. A study comparing four calculation models found significant variations between algorithms. While the Vermeulen formula proved to be the most robust across varying hormone levels, it still showed a systematic positive bias compared to dialysis.
Furthermore, some formulas assume a fixed, standardized albumin concentration (such as 4.3 g/dL) rather than using a patient's actual measured albumin. In patients with altered albumin levels, such as those with liver disease, inflammatory disorders, or malnutrition, this assumption introduces immediate mathematical error.
A calculated result is entirely dependent on the quality of its inputs. If the total testosterone or SHBG test is inaccurate, the calculated free testosterone result will be inaccurate as well.
Research shows that different automated laboratory platforms measure SHBG with variable precision. A 2020 study evaluated multiple commercial SHBG immunoassay analyzers and found significant variation across platforms. When those different SHBG values were entered into the same free testosterone formula, the resulting calculations changed the clinical classification of patients from normal to low.
If your doctor calculates free testosterone using total testosterone measured by an uncalibrated platform, the final calculated number cannot be trusted.
Reference intervals for free testosterone are not standardized across medicine. A healthy reference range established for an equilibrium dialysis assay cannot be applied to a calculated result or a direct immunoassay.
In a 2023 study evaluating healthy, non-obese men using standardized equilibrium dialysis, researchers established specific reference percentiles for free testosterone:
For young, healthy men aged 19 to 39 years within that same cohort, the values were noticeably higher:
These values illustrate the normal biological distribution within a strictly defined, healthy population using a standardized dialysis protocol. Applying these exact numbers to a calculated free testosterone result from a different commercial lab would lead to diagnostic errors.
Evaluating hormone testing research requires separating established clinical guidelines from preliminary laboratory trials.
The clinical recommendations regarding free testosterone testing are supported by strong consensus from major medical organizations:
These recommendations represent high-level clinical guidance designed to prevent misdiagnosis.
While equilibrium dialysis is the scientific
reference method, calling an assay equilibrium dialysis does not automatically make it flawless. The procedure is vulnerable to laboratory conditions.
A method development study conducted by the Centers for Disease Control and Prevention (CDC) evaluated how different dialysis device designs impact results. The researchers found that the volume ratio of the serum sample to the dialysis buffer dramatically altered accuracy.
When testing a dialysis device with a 1:1 sample-to-buffer volume ratio, the mean bias remained under 15 percent compared to reference standards. However, when using a device configuration with a high sample-to-buffer ratio, the analytical bias surged to 50 percent. Diluting the serum shifts the binding equilibrium, causing bound testosterone to dissociate from proteins during the test.
This CDC research demonstrates that equilibrium dialysis must follow strict standardization protocols to achieve its theoretical accuracy.
The evidence disproving direct analog immunoassays is definitive. In an experimental study evaluating assay mechanisms, researchers passed serum samples through equilibrium dialysis membranes. They then tested both the dialysate (containing free hormone) and the retentate (containing protein-bound hormone) using a direct analog immunoassay.
The direct analog assay failed completely to detect free testosterone in the protein-free dialysate. Instead, it generated strong signals only in the retentate containing SHBG and albumin. The assay reacted to total hormone concentrations and binding proteins rather than measuring unbound testosterone. These findings confirm that direct analog tests produce invalid results in clinical practice.
When reviewing a laboratory report that includes free testosterone, following a structured evaluation process prevents errors.
Look closely at the lab report to identify the exact methodology. The report should state whether the test was performed using equilibrium dialysis, mathematical calculation, or direct immunoassay. If the report lists only direct free testosterone without describing dialysis or calculation, assume it is an analog immunoassay and discuss retesting with your doctor.
Confirm the units of measurement listed on the report. Free testosterone is commonly reported in pg/mL, ng/dL, or pmol/L. Always evaluate your numerical result against the specific reference interval provided on that exact page. Never compare a number from one lab to a range published on a medical website or a past test from a different facility.
Never look at free testosterone in isolation. Review your total testosterone, SHBG, and albumin values simultaneously. Determine whether your total testosterone is normal, borderline, or low. Then check whether SHBG is elevated or suppressed, which provides context for why the total and free numbers may diverge.
If your result is calculated free testosterone, determine which formula was used. Check whether your serum albumin was physically measured from your blood sample or entered as a default static value. Confirm that the total testosterone and SHBG inputs were measured using reliable assay methods.
Laboratory numbers are only one piece of a clinical evaluation. Discuss your results alongside your physical symptoms, medical history, medications, and lifestyle factors. True clinical hypogonadism requires both consistently low hormone levels on repeated morning blood tests and clear, consistent clinical signs. Review our low testosterone clinical definitions for deeper context on diagnostic criteria.
These clinical patterns demonstrate how total testosterone, SHBG, and free testosterone interact in daily medical practice. They serve as educational examples rather than diagnostic rules.
A 48-year-old man with moderate obesity and type 2 diabetes presents for routine metabolic blood work. His morning total testosterone returns at 240 ng/dL, which is below the standard normal cutoff. His doctor orders an SHBG test and an equilibrium dialysis free testosterone test.
His SHBG level returns at 12 nmol/L, which is significantly below the normal range due to insulin resistance. His equilibrium dialysis free testosterone returns at 115 pg/mL, well within the normal reference range for healthy men.
In this pattern, low SHBG reduces the total amount of protein-bound hormone in circulation, pulling total testosterone down. However, his circulating free hormone concentration remains adequate. Prescribing testosterone therapy based solely on the low total testosterone number would be inappropriate.
A 58-year-old man reports persistent fatigue, reduced muscle mass, and low libido. His morning total testosterone returns at 480 ng/dL, which appears completely normal. Because his clinical symptoms match androgen deficiency, his doctor orders follow-up testing for SHBG and calculated free testosterone.
His SHBG level returns at 72 nmol/L, which is elevated due to age-related shifts in liver protein production. His calculated free testosterone returns at 42 pg/mL, which sits well below the normal threshold.
In this pattern, excess SHBG binds a disproportionately large fraction of circulating testosterone. This leaves an inadequate supply of unbound, biologically active hormone in circulation despite a normal total testosterone level.
A 35-year-old man uses an online health service that orders a direct free testosterone immunoassay. The test reports an alarmingly low free testosterone value of 4.2 pg/mL. Anxious about the result, he visits an endocrinologist for a formal evaluation.
The endocrinologist runs a comprehensive panel using liquid chromatography-tandem mass spectrometry for total testosterone, a validated SHBG assay, and equilibrium dialysis for free testosterone. The new total testosterone is 550 ng/dL, SHBG is 34 nmol/L, and dialysis-measured free testosterone is 145 pg/mL, entirely normal.
The original direct analog test generated a false-low result because the chemical tracer bound non-specifically to plasma proteins. This scenario highlights why medical guidelines advise against relying on direct analog kits.
A patient has blood drawn at two different clinic systems within the same month. Both clinics report calculated free testosterone using identical input values: total testosterone of 400 ng/dL, SHBG of 45 nmol/L, and albumin of 4.3 g/dL.
Clinic A uses the standard Vermeulen formula and reports a free testosterone of 74 pg/mL. Clinic B uses an alternative equation that applies different association binding constants and reports a free testosterone of 56 pg/mL.
Even though the biological blood sample and input numbers were identical, the two formulas generated numbers that differed by over 25 percent. This discrepancy illustrates why patients must look at the specific formula and reference interval used by the testing laboratory.
A patient has equilibrium dialysis testing performed at two different commercial reference laboratories. Laboratory A reports a free testosterone of 110 pg/mL, while Laboratory B reports 155 pg/mL from a sample drawn under similar physiological conditions.
An evaluation of laboratory protocols reveals that Laboratory A used a 1:1 sample-to-buffer volume ratio under strict temperature regulation. Laboratory B used a high-volume buffer chamber that diluted the serum sample, causing loosely bound hormone to dissociate across the membrane during incubation.
This case demonstrates that technical execution and buffer dilution matter even when using gold-standard dialysis methods. If you are exploring therapy options, check our overview of testosterone replacement therapy evidence.
Several widespread misconceptions lead to confusion when patients and practitioners review hormone tests.
Preparing specific questions helps you have a productive, informed conversation with your healthcare provider about your lab results.
Revisit this guide whenever you receive a new hormone lab report, switch to a new testing laboratory, or undergo a clinical evaluation for changing symptoms. Reviewing these testing methods will help you evaluate your laboratory data accurately alongside your physician.
Understanding how laboratory methods measure free testosterone provides the clinical context needed to interpret your results safely, ask better questions, and make sound healthcare decisions.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
